Organizations/
Businesses

Return to Work/Learn | Stay at Work programs offered Through LabCorp Employer Services

Screening and Testing Programs

LabCorp Employer Services is committed to supporting organizations,
businesses and universities get back to work and learning safely.

Temperature Check Female with Glasses

Symptom Checking

Temperature Check Female

Return to Work | Stay at Work

LabCorp Employer Services, a leading provider of biometric testing services, population health and comprehensive workforce strategies, has recently launched employee on-site or remote COVID-19 screening and testing services designed to support overall health care, risk management and employer Return to Work/Stay at Work strategies. These services use testing by LabCorp Employer Services personnel located throughout the country and are powered by the diagnostic testing capabilities of LabCorp laboratories.

Wellness and COVID-19 Screenings in One

Along with offering complete workforce strategies for employers, LabCorp’s Employer Services assists organizations in identifying employees with elevated temperatures and other possible COVID-19 symptoms who are reporting to work during the COVID-19 pandemic, or requesting to return/stay at the corporate location.

Both services consist of a simple, two-step process managed by on-site trained staff:

  1. Completion of a questionnaire to screen for symptoms that may be consistent with COVID-19
  2. Performance of a no-contact temperature check

Testing Options for COVID-19

COVID-19 Active Infection Swab Testing

Many employees or students may not present with any active symptoms (asymptomatic). LabCorp Employer Services can test asymptomatic patients at the office or home.

On-site: The COVID-19 PCR test uses a self-collection nasal swab to detect the presence of the virus that causes COVID-19. LabCorp Employer Services staff are on-site to assist with sample collection, sample preparation and sample shipments, with results available on average in 2-4 days.

Off-site: We offer a COVID-19 test at-home collection kit, which detects the presence of the virus that causes COVID-19 via a self-administered nasal swab, and can be sent directly to employees at their home with results available on average in 2-4 days upon receipt of sample. The at-home collection test kit has received Emergency Use Authorization from the U.S. Food and Drug Administration.

For employees with active COVID-19 symptoms, they should contact their doctor or healthcare provider.

COVID-19 IgG Antibody Blood Testing

Antibody testing is for individuals who think they may have previously had COVID-19 and do not currently have symptoms. It can check for antibodies that may have developed after exposure to the virus that causes COVID-19. Note: antibody testing should not be used as the sole basis to diagnose or exclude infection.

On-site: The COVID-19 antibody test determines the presence of antibodies to SARS-CoV-2, the virus that causes COVID-19, and helps identify individuals who may have been exposed to the virus. This test is available as a dried blood spot fingerstick test or as a blood draw, both of which can be performed conveniently at your facility, with results available on average in 2-4 days.

Off-site: The COVID-19 antibody test is a blood draw test, performed at a LabCorp patient service center or convenient LabCorp at Walgreens location. A phlebotomist at the facility will collect and prepare the sample, with results available on average in 2-4 days.

Temporal Thermometer

Get Started

Call LabCorp Employer Services at 1-877-469-5411

Contact Form

To learn more about LabCorp Employer Services’ portfolio of workforce strategies and COVID-19 return to work and school services, complete the form below.

LabCorp’s COVID-19 PCR test has not been FDA cleared or approved, has been authorized by the FDA under an Emergency Use Authorization (EUA), and has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

LabCorp’s fingerstick, or dried blood spot, IgG antibody test is being provided as a laboratory developed test, and uses the Euroimmun platform which received Emergency Use Authorization by the U.S. Food and Drug Administration. LabCorp completed independent validation studies on this testing. The COVID-19 IgG antibody blood test detects the presence of antibodies to the virus and can help determine if an individual may have been exposed to the virus. While antibody tests are helpful to understand if an individual has developed antibodies and a potential immune response, antibody testing should not be used as the sole basis to diagnose or exclude infection.

COVID-19 Information and Resources

Scroll back to top of page